Sartorius Stedim Biotech (CHIX:DIMP) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:DIMP Sartorius Stedim Biotech SA CHIX:DIMP
82 GF Score
Price €184.45
GF Value €202.59
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Sartorius Stedim Biotech Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sartorius Stedim Biotech  (CHIX:DIMp) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Related Terms


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Chart

Sartorius Stedim Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 34.84 16.69 11.40 7.83 8.01

Sartorius Stedim Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.13 6.62 7.95 6.23 6.61

CHIX:DIMP vs ISRG, BDX, RMD: Cyclically Adjusted PS Ratio Comparison

For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sartorius Stedim Biotech Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sartorius Stedim Biotech's Cyclically Adjusted PS Ratio falls into.


CHIX:DIMP
82GF Score
Sartorius Stedim Biotech SA CHIX:DIMP
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius Stedim Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sartorius Stedim Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Sartorius Stedim Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=7.87/131.3638*131.3638
=7.870

Current CPI (Jun. 2026) = 131.3638.

Sartorius Stedim Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 2.997 101.017 3.897
201612 2.891 101.217 3.752
201703 2.916 101.417 3.777
201706 3.006 102.117 3.867
201709 2.809 102.717 3.592
201712 2.978 102.617 3.812
201803 3.049 102.917 3.892
201806 3.304 104.017 4.173
201809 3.367 104.718 4.224
201812 3.429 104.217 4.322
201903 3.720 104.217 4.689
201906 3.975 105.718 4.939
201909 3.986 106.018 4.939
201912 3.947 105.818 4.900
202003 4.579 105.718 5.690
202006 4.849 106.618 5.974
202009 5.537 105.818 6.874
202012 5.757 105.518 7.167
202103 7.108 107.518 8.684
202106 7.558 108.486 9.152
202109 8.212 109.435 9.858
202112 8.442 110.384 10.047
202203 9.357 113.968 10.785
202206 9.349 115.760 10.609
202209 9.530 118.818 10.536
202212 9.656 119.345 10.628
202303 7.878 122.402 8.455
202306 7.331 123.140 7.821
202309 7.236 124.195 7.654
202312 7.669 123.773 8.139
202403 6.895 125.038 7.244
202406 7.259 125.882 7.575
202409 6.735 126.198 7.011
202412 7.721 127.041 7.984
202503 7.653 127.779 7.868
202506 7.657 128.412 7.833
202509 7.253 129.255 7.371
202512 7.937 129.361 8.060
202603 7.827 131.258 7.833
202606 7.870 131.364 7.870

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued. The current stock price of €184.45 is trading 9% below its estimated GF Value™ of €202.59. GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.

Key valuation signals for CHIX:DIMP:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €202.59 vs. price of €184.45 (9% below fair value)
  • GF Score™: 82/100 with 5 warning signs

No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sartorius Stedim Biotech Business Description

Address Otto-Brenner-Strasse 20, Goettingen, DEU, 37079
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
82GF Score

Get the complete analysis for CHIX:DIMP

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€184.45
Price
€202.59
GF Value